Audit: QRS - DSIP for Health & Longevity

Audit conducted on 05/08/2026 10:26 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	91
Passed	82
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked all populated spans against the ER: protocol values (ER 367, 375, 377, 379, 381), time-to-effect (ER 424), benefit/risk tier headings (ER 151–305), gate items (ER 323–343), all 11 biomarker rows and targets (ER 452–462), cadence (ER 446–448) and all 7 qualitative markers (ER 466–472).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	At-A-Glance keeps “Evidence remains preliminary and unresolved” (ER 502) and “the supply is unverified” (ER 500); speculative tiers stay in the Speculative bucket.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	“Pregnancy and lactation at any exposure” stays an absolute Contraindication; general anaesthetics stays absolute rather than being downgraded to a Key Interaction.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	No content from Benefit-Modifying Factors (ER 230–240) or Risk-Modifying Factors (ER 310–318) appears in the gates or the Risks card.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, author names or NCT identifiers anywhere in the QRS; the drug names in the Key Interactions gate are the ER’s own parenthetical lists (ER 323–341).
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Sceptical-but-neutral register of the ER Conclusion (ER 498–502) is carried through unchanged.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Presents the evidence split, the practice protocol, and the measurable endpoints so the reader can act on data rather than on assertion.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol cells are framed as what practitioners do (“Standard practitioner protocol”), not as instructions.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives, no “should”, no “take”/”use” directed at anyone.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Every cell is declarative reporting of ER content.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	“rapid eye movement sleep” is spelled out in qualitative item 4; remaining technical terms are unavoidable biomarker names.
2.8	Information is presented in a concise and very compact manner	🟢	Gate items, benefit and risk tiers are short noun phrases; the “Why” column entries are 4–8 words.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content assumes willingness to run a 7-night baseline, an 11-marker blood panel and daily qualitative tracking.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Subcutaneous self-injection, cycling schedules and continuous autonomic measurement are presented without hedging about effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification toward a mass-market reader; the sourcing and characterization risk is stated plainly.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Highest-graded risk is the grey-market supply chain, which is the risk specific to this audience rather than to the general population.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; “Other longevity peptides” is used in the Key Interactions gate.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“subcutaneously”, “injection-site reactions”, “adverse”-register terms used throughout; no colloquialisms.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All 15 fixed strings verified byte-identical to the template (QRS.html 437, 474, 516, 536, 542, 553, 572, 576–578, 603).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	74 data-qrs-var spans, all unique: page_title, header_topic/subline_date/subline_model, at_a_glance, action_1–3 × label/value/sub, time_1–3 × label/value/sub, benefits ×4, stop_items, caution_items, risks ×4, marker_1–11 × name/target/why, monitoring_cadence, qualitative_item_1–7. The repeatable marker_#_* and qualitative_item_# rows are correctly expanded.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff of QRS lines 16–407 against template lines 1–404 shows zero deviation outside [page_title]; the non-variable website="evidence_review", website="audit" and website="full_review" spans, the stale “Time to Effect row (4 cells, 2×2)” template comment and the full stylesheet are all preserved verbatim.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the only empty tier is Benefits/High, which item 12.5 governs via display: none.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard practitioner protocol”, “Best time of day”, “Route selection” (ER 367, 375, 381) and all 7 qualitative labels (ER 466–472) are carried over verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect labels (“Night sleep”, “Subjective response”, “Sleep architecture”) are lifted from the wording of the ER’s Time to effect bullet (ER 424) rather than invented.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the file; the ER’s “⚠️ Conflicted” markers on three benefit/risk headings were correctly stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to the minimum consistent with the completeness mandates of 8.2, 9.2, 14.2 and 15.2 — gate items are single clauses, benefit/risk tiers are semicolon lists of bare headings, and “Why” cells are reduced from full ER sentences to 4–8 word fragments. No section is elaborated beyond its budget.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the “QRS — Metadata” caption precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is echoed into the body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	No trailing whitespace on any line; only duration: "00:04" is quoted, and it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: dsip_2026-0805-0757_Opus_ER.md (line 4).
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02 (line 5), matching QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0805-1003 (line 6).
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus (line 7).
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5 (line 8).
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: dsip_2026-0805-0757_Opus_QRS.html (line 9), matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys including the appended duration, git_user, git_issue.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“DSIP for Health & Longevity - Quick Reference Sheet” (line 22); canonical_topic is “DSIP for Health & Longevity” (ER line 8).
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“DSIP for Health & Longevity” (line 417).
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0805-1003 → “08/05/2026” (line 421).
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5” (line 425).
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline; the ER’s “Also known as” line (ER 30) was correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses ER 498–502 into the five decision-relevant facts: origin/mechanism gap, split human record, animal-only aging data, mild side-effect profile, unverified supply.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Mapped 1:1 to ER 498 (rabbits, fifty years, no gene/docking site; handful of small decades-old studies; split result; rodent-only aging data), ER 500 (mild side effects, unverified supply) and ER 502 (“the evidence remains preliminary and unresolved”).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “docking site” is used in place of “receptor”, following the ER’s own plain-language choice.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No study names, years, n-values or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect measures of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items trace to ER 327 and ER 343.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete: the seven “Populations who should avoid DSIP” entries (ER 343) plus the general-anaesthetic absolute contraindication (ER 327).
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Eight discrete <li> elements (lines 577–587).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s rationale clauses (“since no reproductive toxicity data exist”, “given the documented rise in heart rate…”, the anti-doping explanation) are all stripped; no dashes appear in any item.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Retained: “at any exposure”, “in the perioperative window”, “within 7 days”, “(apnoea-hypopnoea index of 15 or more events per hour) until the airway is treated”, “within 90 days”, “under anti-doping jurisdiction”.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in Key Interactions & Contraindications.
8.7	If no [stop_items] are present the section is left empty	N/A	Eight stop_items are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items trace to ER 323–341.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Eight of ten ER bullets carried over; general anaesthetics correctly excluded (already a Contraindication) and OTC analgesics excluded (ER 333 states “No known interaction”).
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eight discrete <li> elements (lines 595–608).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “Mitigation described in practice” clause is stripped; the ER’s inline em-dash glosses (GABA, 5-HTP, SSRIs, growth hormone secretagogues) are removed rather than carried through.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All named-drug lists preserved: benzodiazepines, opioids, antihistamines, sedating supplements, serotonergic agents and longevity peptides; “Melatonin (additive)” preserves the ER’s “specifically additive” qualifier.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	If no [caution_items] are present the section is left empty	N/A	Eight caution_items are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Drawn from the ER Therapeutic Protocol section (ER 367–389).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose and cycling schedule, administration timing, and route — the three decisions required before a first dose.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies well over three actionable aspects; all three sets are populated.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated: “100 to 300 µg subcutaneously” (ER 367), “Evening” (ER 375), “Subcutaneous” (ER 381); subs draw on ER 367, 377, 379, 381.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	First-dose night-sleep response, 1–3 night subjective response, and 2–4 week sleep-architecture assessment — the three horizons stated at ER 424.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered from the strongest reported endpoint (night sleep, the Medium-tier sleep-efficiency benefit) through subjective response to the objective architecture read-out.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct aspects exist and all three sets are populated.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated; values “First dose”, “1 to 3 nights”, “2 to 4 weeks” match ER 424 exactly.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (ER 424), so the section is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All twelve entries map to the ER benefit headings at ER 151–225.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present (lines 544–567).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the ER heading reduced to a bare noun phrase; every “Magnitude” figure, mechanism sentence and evidence-basis sentence is dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any benefit entry.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	ER states no benefit reaches the High tier (ER 153); benefits_high carries style="display: none" with no empty-state text (lines 544–546). Medium/Low/Speculative are populated with 2, 7 and 3 entries respectively.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All ten entries map to the ER risk headings at ER 247–305.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present (lines 620–643).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	The 2026 advisory-vote detail, the burst-suppression explanation and all “Magnitude” text are dropped; entries are bare noun phrases.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any risk entry.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers contain items in the ER, so no tier needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Derived from the ER Monitoring Protocol & Defining Success table (ER 450–462).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 11 ER table rows present in the same order with targets copied verbatim: slow-wave sleep %, sleep-onset latency, overnight HRV, resting overnight heart rate, morning cortisol, HbA1c, fasting insulin, hs-CRP, ALT and AST, CBC with differential, creatinine with eGFR.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Condenses ER 446 and ER 448: baseline with ≥7 nights of sleep measurement, continuous sleep/autonomic measures reviewed at 2 and 8 weeks, blood panel at 8–12 weeks then every 6–12 months.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Derived from the qualitative-marker list at ER 466–472.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All 7 present with the ER’s bold labels verbatim: sleep quality on waking, morning sleep inertia, daytime alertness and cognitive clarity, dream recall and dream character, mood and emotional stability, headache, injection site appearance.

Issues 05/08/2026 10:26

Pass rate 100.00%. No issues found.

Issues 05/08/2026 10:18

1. 4.5 — One-page budget exceeded: The Monitoring “Why” cells (lines 667–805), the cadence paragraph (lines 813–816), and the Qualitative Assessment descriptions (lines 826–864) carry the ER’s full sentences verbatim instead of being condensed to the per-section budget, pushing the sheet past a single A4 page at the template’s print width.

Fixes 05/08/2026 10:18

1. 4.5 — Monitoring “Why” cells condensed: All ten multi-line “Why” cells were shortened to single-line form, e.g. “Rising eosinophils are the earliest signal of an allergic response to an impure peptide preparation” became “Rising eosinophils are the earliest allergic signal”.
2. 4.5 — Monitoring cadence condensed: The cadence paragraph was cut from ~335 to ~230 characters while keeping the baseline, the 2- and 8-week reviews, the 8–12-week panel, and the 6–12-month interval.
3. 4.5 — Qualitative descriptions condensed: Four of the seven qualitative-marker descriptions were tightened to fit one line each, e.g. “presence, timing, and severity, since it is the recognized signal that the dose has been exceeded” became “presence, timing, and severity; the recognized dose-exceeded signal”.

Issues 05/08/2026 10:10

1. 9.4 — Trailing clauses in Key Interactions: In [caution_items] the entries “Serotonergic agents (SSRIs, 5-HTP): monitor” and “Over-the-counter analgesics (ibuprofen, naproxen, paracetamol): no known interaction” carry trailing explanatory clauses instead of the bare key fact, and the analgesics entry states a non-interaction inside a caution decision gate.

Fixes 05/08/2026 10:10

1. 9.4 — Trailing clauses in Key Interactions: Stripped “: monitor” from the serotonergic agents entry and removed the “Over-the-counter analgesics (ibuprofen, naproxen, paracetamol): no known interaction” entry entirely, since an explicit non-interaction does not belong in the Key Interactions decision gate.